NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOL
HEIDELBERG, Germany, and CAMBRIDGE, Mass., April 26, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical...
Source: europapress.es